🚀 LungLife AI Impresses Investors
posted 2 Jan 2024
Shares of the American firm LungLife AI, engaged in developing AI-driven diagnostic techniques for lung cancer, have seen a notable increase, peaking at a 60% rise. This boost came in the wake of publishing successful results from their LungLB test.
This test demonstrated an 81% accuracy in detecting small cancer formations, a figure that substantially exceeds the average accuracy of current methods, which is around 60%. Considering that small tumors represent 87% of lung cancer cases, these findings are particularly significant.
More breaking news
